Neovasc Inc. Capital Stock Change

Capital Stock Change of NVCN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital Stock Change growth rates and interactive chart.


Highlights and Quick Summary

  • Capital Stock Change for the quarter ending December 31, 2021 was $0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Capital Stock Change decreased by -100.0%
  • Annual Capital Stock Change for 2021 was $66.4 Million (a 46.35% increase from previous year)
  • Annual Capital Stock Change for 2020 was $45.4 Million (a 118.11% increase from previous year)
  • Annual Capital Stock Change for 2019 was $20.8 Million (a 50.56% increase from previous year)
  • Twelve month Capital Stock Change ending December 31, 2021 was $66.4 Million (a -7.28% decrease compared to previous quarter)
  • Twelve month trailing Capital Stock Change decreased by -35.54% year-over-year
Trailing Capital Stock Change for the last four month:
31 Dec '21 30 Sep '21 30 Jun '21 31 Mar '21
$66.4 Million $71.6 Million $87.9 Million $103 Million
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital Stock Change of Neovasc Inc.

Most recent Capital Stock Changeof NVCN including historical data for past 10 years.

Interactive Chart of Capital Stock Change of Neovasc Inc.

Neovasc Inc. Capital Stock Change for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.0 $0.0 $0.0 $66.4 $66.4
2020 $5.22 $16.31 $15.08 $8.76 $45.37
2019 $0.0 $0.0 $11.48 $9.32 $20.8
2018 $0.73 $0.0 $13.07 $0.02 $13.82
2017 $0.02 $0.01 $0.21 $0.02 $0.25
2016 $7.05 $0.0 $0.03 $0.05 $7.13
2015 $70.97 $0.04 $70.74 $70.97
2014 $22.29 $22.29

Business Profile of Neovasc Inc.

Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.